Cardiovascular Systems Inc

Cardiovascular Systems — Q4 FY2021 Earnings Presentation

13 slides from Cardiovascular Systems's earnings presentation, Aug 4, 2021

  1. Slide 1: Q4 FY21 Earnings Supplement

    ©2021 Cardiovascular Systems, Inc. All Rights Reserved. Q4 FY21 Earnings Supplement August 4, 2021

  2. Slide 2: Safe Harbor

    Safe Harbor This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Report Act of 1995, which are provided under the protection of the safe harbor for forward-looking statements provided by that Act. For example, statements in this presentation r

  3. Slide 3: Q4 FY21 Worldwide Revenues of $71 Million

    66.8% increase vs. LY and 12.2% sequential growth vs. Q3 FY21 Q4 FY21 Worldwide Revenues of $71 Million Q4 FY21 Revenue Breakdown Worldwide Peripheral $47.8 +55.7% Y/Y +12.9% Q/Q Worldwide Coronary $23.2 +95.7% Y/Y +10.7% Q/Q Worldwide Peripheral Worldwide Coronary ($ in millions, Y/Y and Q/Q repres

  4. Slide 4: FY21 Worldwide Revenues of $259 Million

    9.5% increase vs. FY20 FY21 Worldwide Revenues of $259 Million *Excludes $20.8M financing obligation for lease payments on company headquarters FY21 Revenue Breakdown Worldwide Peripheral $176.9 +6.3% Y/Y Worldwide Coronary $82.0 +17.0% Y/Y Worldwide Peripheral Worldwide Coronary ($ in millions, Y/Y

  5. Slide 5: Q4 FY21: U.S. Peripheral

    Q4 FY21: U.S. Peripheral 1 Is the total of Orbital Atherectomy System Revenue plus Interventional Support Device Revenue. 2 Includes peripheral orbital atherectomy devices, ViperWire, ViperSlide, Exchangeable cartridges, ViperTrack and other 3 Zilient Guidewires, ViperCath and WIRION 13.2% sequentia

  6. Slide 6: Q4 FY21: U.S. Coronary

    Q4 FY21: U.S. Coronary 1 Is the total of Orbital Atherectomy System Revenue plus Interventional Support Device Revenue. 2 Includes coronary orbital atherectomy devices, Coronary ViperWire, ViperSlide and other 3 Includes Sapphire angioplasty balloons and Teleport microcatheters Strong case volume dr

  7. Slide 7: Q4 FY21: International

    Q4 FY21: International Exiting FY21 with increased case volume despite pandemic pressures 7 International revenue increased 76.4% Y/Y • International revenue increased 0.4% sequentially vs. Q3 FY21 • Number of OUS cases exceeded 2,000 for the first time • Certified and trained 97 new physicians usin

  8. Slide 8: Q4 FY21 vs. Q3 FY21 and Q4 FY20

    Q4 FY21 vs. Q3 FY21 and Q4 FY20 Dollars in thousands 8 Q4 FY21 Quarter/Quarter Change Year/Year Change Worldwide Revenue $70,987 12.2% 66.8% Worldwide Peripheral Revenue $47,758 12.9% 55.7% Worldwide Coronary Revenue $23,229 10.7% 95.7% U.S. Revenue $67,293 12.9% 66.4% U.S. Peripheral Revenue $47,64

  9. Slide 9: Q4 FY21: Select Financial Information

    Q4 FY21: Select Financial Information Dollars in thousands, except earnings per share 9 Q4 FY21 Q3 FY21 Q/Q Change Fav (Unfav) Q4 FY20 Y/Y Change Fav (Unfav) Net revenues $70,987 $63,273 $7,714 $42,546 $28,441 Cost of goods sold 20,634 14,013 (6,621) 10,144 (10,490) Gross Margin 70.9%** 77.9% Decrea

  10. Slide 10: FY22: Annual Guidance

    FY22: Annual Guidance 10 For the fiscal year ending June 30, 2022, CSI anticipates: Revenue of $295 million to $305 million (14% to 18% growth); Gross profit as a percentage of revenues of approximately 76%; Net loss in a range of 2% to 3% of revenues; and Adjusted EBITDA of 6% to 8% of revenues.

  11. Slide 11: Non-GAAP Financial Measures

    Non-GAAP Financial Measures 11 CSI uses Adjusted EBITDA as a supplemental measure of performance and believes this measure facilitates operating performance comparisons from period to period and company to company by factoring out potential differences caused by depreciation and amortization expense

  12. Slide 12: Investor Contact

    Investor Contact: Jack Nielsen 651-202-4919 [email protected] CSI®, Diamondback®, Diamondback 360®, GlideAssist®, ViperWire®, WIRION® and ViperWire Advance® are trademarks of Cardiovascular Systems, Inc. © 2021 Cardiovascular Systems, Inc. OrbusNeich®, Teleport® and Sapphire® are trademarks of Or

  13. Slide 13: Cardiovascular Systems, Inc.

    CARDIOVASCULAR SYSTEMS, INC. cSi www.csi360.com

Cardiovascular Systems — Q4 FY2021 Earnings Presentation on 6ix